Speakers



Professor April Armstrong

April Armstrong, MD, MPH, is the associate dean for clinical research at the Keck School of Medicine of USC. She serves as director of Clinical Research Support at the Southern California Clinical and Translational Science Institute, vice chair and director of Clinical Trials and Outcomes Research, and director of the Psoriasis Program in the Department of Dermatology at USC. She obtained her medical degree and completed her dermatology residency at Harvard Medical School. She earned her Master of Public Health in clinical effectiveness degree from the Harvard School of Public Health.



Participates in the following:
Friday 2/7 16:00-17:00 - More than skin deep – Global psoriatic disease beyond survey
Wednesday 30/6 12:50-13:00 - Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Compared With Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Efficacy and Safety Results From the Phase


Professor Darren Ashcroft

Prof Ashcroft is the Professor of Pharmacoepidemiology at The University of Manchester. He has conducted research focussed on improving care for people with dermatological conditions for over 25 years, working very closely with the Manchester Dermatology Centre. 


 


He is the founding Director of Research for the Global Psoriasis Atlas; the first ever, comprehensive global database on the epidemiology of psoriasis. In developing this important resource, he works closely with the International Federation of Psoriasis Associations (IFPA), the International League of Dermatological Societies (ILDS) and the International Psoriasis Council (IPC). 



Participates in the following:
Wednesday 30/6 13:00-14:00 - Global Psoriasis Atlas: Latest research update & projects


Professor Matthias Augustin

Prof. Augustin|Chairs: health economics dermatology, University Medical Center Hamburg|Founding director: Institute for Health Services Research in Dermatology and Nursing, Hamburg Institute for Health Economics|Research focus: health services, health economics, epidemiology clinical |Main indications: psoriasis, atopic eczema, allergies, chronic wounds, skin cancer|Authored: 27 medical books, about 710 scientific medical papers|Involved in atopic eczema & psoriasis networks, German skin cancer assembly, WHO projects, national international level|Senior consultant: German Ministry of Health (GBA), health insurance, pharma companies



Participates in the following:
Thursday 1/7 10:00-10:50 - Interactive discussion session
Saturday 3/7 11:10-11:35 - Strategies to reduce stigma – learnings from the German national programme against stigmatization


Frank Behrens


Participates in the following:
Friday 2/7 10:00-11:00 - Plenary/symposium session - Comorbidity update
Friday 2/7 11:10-11:50 - Can we prevent progression to psoriatic arthritis?


Professor Anthony Bewley

Professor Anthony Bewley qualified from Bristol University Medical School in 1987, and has trained in Dermatology at the Westminster Hospital, University College London Hospitals, Portsmouth and Southampton University Hospitals NHS Trust. He is a Consultant Dermatologist at Barts Health NHS Trust; and Honorary Professor at Queen Mary College (University of London). He is fully trained in general dermatology, and has a special interest in psychodermatology (psycho-cutaneous medicine). He is the lead for clinical trials research at the Barts Health Dermatology Department, and has published extensively in international peer-reviewed journals on a range of different areas within dermatology. Dr Bewley was Chair of Psychodermatology UK 2008-20; President of the UK Dowling Dermatology Club 2019-20 and is currently Hon Treasurer of the British Association of Dermatologists. He is the co-editor of Practical Psychodermatology (Wiley, 2014), Clinical Psychodermatology (Springer 2021) and associate editor of Rooks Textbook of Dermatology (Wiley 2016); he is Secretary and President Elect of the European Society for Dermatology and Psychiatry (ESDaP; www.psychodermatology.net) and runs training schools for health care professionals in psychodermatology.



Participates in the following:
Thursday 1/7 16:00-17:00 - Session 4: Psoriatic disease and its impact on mental health
Thursday 1/7 16:00-17:00 - Psychotherapy and psoriasis


Barbra Bohannan

Ms Bohannan is the Secretary of the Scientific Executive Committee for the 6th World Psoriasis & Psoriatic Arthritis Conference. She currently serves as Coordinator for advocacy, policy and research at Psoriasisförbundet. Previously, she was the Head of Operations for the International Federation of Psoriasis Associations, IFPA. She has served on the Steering Committee of the Global Psoriasis Atlas project, contributed to the WHO Global report on psoriasis, and has authored several informational/educational articles in both international and national journals and magazines.



Participates in the following:
Friday 2/7 16:00-17:00 - Improving treatment and care at primary care setting - Learnings from Sweden


Professor Luca Borradori


Participates in the following:
Wednesday 30/6 13:00-14:00 - Improving access to care


Professor Christine Bundy

Chris specialises in psychological management of complex inflammatory conditions. She is a behaviour change expert with a focus on adherence and patient self-management in inflammatory skin and joint disease.


Chris was President of the UK Society for Behavioural Medicine from December 2014-2016 and has served on two NICE clinical guideline development groups, and three research Priority Setting Partnership groups. She is currently working on 2 EU Guideline development groups.


Chris also is a member of the Covid-19 technical advisory group to the Welsh Government.



Participates in the following:
Thursday 1/7 11:00-11:45 - Self-responsibility and self-management – encouraging lasting behaviour change in patients with psoriasis/psoriatic arthritis


Professor Kristina Callis Duffin

Kristina Callis Duffin, MD, MS is Professor and Chair of the Department of Dermatology at the University of Utah. She is an internationally recognized expert in psoriasis and has led over 50 clinical trials and observational studies in psoriasis and other skin diseases. She currently serves as President of GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and is Vice-Chair/Chair-Elect of the National Psoriasis Foundation Medical Board.



Participates in the following:
Thursday 1/7 14:00-14:45 - Joint IFPA/ GRAPPA session; Palmoplantar pustulosis
Thursday 1/7 15:00-15:45 - Introduction


Professor Vinod Chandran

I am a Rheumatologist and clinician-scientist, an Associate Professor of Medicine at the University of Toronto, and a scientist at the Schroeder Arthritis Institute, University Health Network, Toronto. I co-direct the Psoriatic Disease Program at the University Health Network. My research interests lie in the genetic and molecular epidemiology of psoriasis and psoriatic arthritis, and the identification of molecular psoriatic arthritis biomarkers. My research is supported by the Canadian Institutes of Health Research, the National Psoriasis Foundation, and the Krembil Foundation.



Participates in the following:
Wednesday 30/6 10:30-11:10 - Pathogenesis of psoriatic arthritis


Professor Laura Coates

Laura Coates, MBChB, PhD, Associate Professor, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, UK


Laura Coates is an Associate Professor awhose research focuses on optimal therapeutic strategies in psoriatic arthritis (PsA). Her PhD focused on the development of the minimal disease activity criteria for PsA and establishment of the TICOPA trial. Her research is clinical and focuses on psoriatic arthritis and the spondyloarthritides. She is chair of the British PsA Consortium (BritPACT).



Participates in the following:
Friday 2/7 12:10-13:00 - Treatment strategies – unmet needs of treating psoriasis/psoriatic arthritis


Orla Coleman


Participates in the following:
Friday 2/7 11:50-12:00 - Identification of serum protein biomarkers at baseline to distinguish radiographic progressors from non-progressors in patients with active Psoriatic Arthritis (PsA).


Dr. Curdin Conrad

Dr. Curdin Conrad is Professor of Dermatology and head of policlinic and the center for psoriasis at Lausanne University Hospital in Switzerland. He received his MD training at the University of Zurich, where he also participated at the Postgraduate Course of Experimental Medicine and Biology. After his training in Dermatology, he was research fellow at MD Anderson Cancer Center in Houston, Texas.

Dr. Conrad has a strong interest - from basic science to translational research and the clinic - in inflammatory skin diseases, adaptive and innate immunity, and targeted immunotherapies. He has fundamentally contributed to today's understanding of the pathogenesis of psoriasis and has received several scientific awards for his basic and translational research. Over the years, Dr Conrad has actively been involved in the teaching of evidence-based clinical and scientific dermatology and immunology. He serves as external scientific expert for several international societies and foundations, is an elected councilor of the International Psoriasis Council, IPC and board member of the ESDR.



Participates in the following:
Saturday 3/7 14:00-14:45 - Psoriasis, psoriatic arthritis and infectious disease


Professor Kurt de Vlam

Kurt de Vlam is Head of Clinic Rheumatology at the University Hospital of Leuven in Belgium and Principal Investigator and Professor of Rheumatology in the Skeletal Biology and Engineering Research Center of the Department of Development and Regeneration,KUL, Belgium . He is the group leader for the clinical research program in spondyloarthropathy, He has authored and co-authored more than 120 papers in international peer reviewed journals and was also involved in a number of multicenter clinical trials from phase I to IV for the treatment of chronic arthritis including PsA.



Participates in the following:
Friday 2/7 12:10-13:00 - Looking back and looking ahead – long-term safety, risk management and future potential


Professor Ignacio Dei-Cas

Ignacio Dei-Cas. Dermatologist specialized in treating psoriasis patients at Pte Perón Hospital in Buenos Aires, Argentina. PhD research in metagenomics and psoriasis. Buenos Aires School of Medicine, Argentina (UBA).



Participates in the following:
Thursday 1/7 13:00-14:00 - Relevance of the gut microbiome to psoriasis


Professor Ncoza Dlova


Participates in the following:
Saturday 3/7 11:10-11:35 - The global need for active measures against stigmatization


Professor Cristina Echeverría

Dr. Echeverría is a medical doctor at IREP (Instituto de Rehabilitación Psicofísica) in Buenos Aires, Argentina. She received a medical degree (Hon) at the University of Buenos Aires (UBA). Three years later, she completed her Internal Medicine Residency and she earned a degree in Dermatology from the University of Buenos Aires (UBA) where she currently serves as an assistant professor in dermatology. Dr. Echeverría was a visiting doctor at Baylor College of Medicine, Houston, Texas. She is currently the President of SOARPSO (Sociedad Argentina de Psoriasis), coordinator of the ECHO Psoriasis and ECHO Atopic Dermatitis Argentina.



Participates in the following:
Friday 2/7 16:00-17:00 - Session 6: Focus on unmet needs: Taking global knowledge and implementation at national level
Friday 2/7 16:00-17:00 - National guidelines implementation – Latest therapeutic guidelines for the management of psoriasis - Argentina


Dr Alexander Egeberg

Dr. Egeberg is a dermato-epidemiologist at the Department of Dermatology and Allergy at Gentofte Hospital. He has received recognition for excellence in dermatological research and has extensive knowledge in publication planning and clinical trial designs, including explorative/post-hoc analysis from phase I-IV studies. He has authored more than 200 scientific publications and textbook chapters. Dr Egeberg’s main research interests are in inflammatory skin diseases, particularly the epidemiology of psoriasis and the development and use of biologic and novel small-molecule therapies.



Participates in the following:
Friday 2/7 11:10-11:50 - Prevention and reduction of disease through weight-loss
Friday 2/7 12:10-13:00 - Potential for prevention of comorbidity


Professor Dirk Elewaut

Dirk Elewaut is a Full Professor or Rheumatology and Immunology and Chari of the Department of Rheumatology and Immunology at Ghent University Hospital, a EULAR and FOCIS cenre of excellence. He has publicshed more than 300 scientific publications in leading sientific jounrals and is Principal Investigator at the VIB Center for Inflammation Research at Ghent University. Currently, he serves as Chair of the EULAR Research Committee. His research interests are centered around translational aspects of immunie regulation to combat inflammatory arthritits and associated joint damage, with a special focus on the link between gut and joint disease in spondyloarthritis



Participates in the following:
Thursday 1/7 12:00-12:45 - The general impact of the microbiome in chronic, inflammatory disease


Lucía Estrada Csaky


Participates in the following:
Thursday 1/7 14:00-14:45 - The challenge of living with PPP- Filmed testimonials from people living with PPP


Professor Andrea Evers Leiden

Prof. Dr. Andrea W.W. Evers is professor of Health Psychology and chair of the Health-Medical-and-Neuropsychology-Unit at Leiden University, the Netherlands. After her PhD (cum laude), she obtained several personal grants and awards for excellent researchers (e.g. NWO-Veni-Vidi-Vici, ERC Consolidator Grant) for her innovative, interdisciplinary and translational research on psychoneurobiological mechanisms and treatments for health and disease. In 2019, she received the Stevin Award, the highest dutch award for scientific research with societal impact. She is a lifetime member of the Dutch Royal Academy of Science and Arts (KNAW).



Participates in the following:
Thursday 1/7 16:00-17:00 - Making use of placebo effects in clinical care for the well-being of psoriasis patients: role of cognitive behavioral therapy


Professor Kilian Eyerich

Kilian Eyerich is chair and professor for Dermatology and Venereology at the Karolinska Institute in Stockholm, Sweden, as well as Heisenberg professor for Dermato-Immunology at the Technical University Munich, Germany. His scientific interest is the interaction of adaptive immune cells and resident epithelial cells in inflammatory skin diseases. His vision is to revise the disease ontology of inflammatory and autoimmune skin diseases based on a clinically meaningfull molecular basis.



Participates in the following:
Friday 2/7 12:10-13:00 - Treatment strategies – unmet needs of treating psoriasis/psoriatic arthritis


Silvia Fernandez Barrio

Journalist radio and TV anchor Advocate Founder of AEPSO in 2005 Founder of the latinamerican network of Psoriasis, LATINAPSO 2009 Board member since 2007 Ex Chair of World Psoriasis Day National and international health speaker Several prices regarding my work as woman advocate in health Psoriasis Patient



Participates in the following:
Thursday 1/7 10:00-10:50 - Listening is learning – the patient perspective
Thursday 1/7 16:00-17:00 - Support group sessions and functioning – an interactive workshop with advocates
Friday 2/7 16:00-17:00 - Introduction – More than skin deep


Professor Oliver FitzGerald

Major interest in clinical and translational research in Psoriatic Arthritis (PsA). More recent studies explore genetic factors and biomarker development. I have been involved for many years with GRAPPA and will take up the office of President in 2021. Have been advocating for grant application opportunities addressing unmet needs in PsA for several years and this has culminated in the first, significant, joint EU/industry funded Innovative Medicines Initiative (IMI) grant in PsA.



Participates in the following:
Wednesday 30/6 10:30-11:10 - Plenary/symposium session – Pathogenesis
Wednesday 30/6 11:10-11:50 - Plenary symposium session – Treatment guidelines
Wednesday 30/6 12:10-12:50 - Plenary/symposium session – New treatments
Thursday 1/7 11:00-11:45 - Keynote lecture
Thursday 1/7 12:00-12:45 - Keynote lecture
Thursday 1/7 15:00-15:45 - Innovative Medicines Initiative grant: Unmet needs in psoriatic arthritis
Friday 2/7 12:10-13:00 - Plenary/symposium session - 20 years of biologics
Saturday 3/7 10:00-11:00 - Interactive discussion session
Saturday 3/7 11:10-11:35 - Unmet needs session continued
Saturday 3/7 14:00-14:45 - Keynote lecture


Kathleen Gallant

Serving on the International Federation of Psoriasis Association's Executive Committee and the National Psoriasis Foundation Board as ex-officio, Kathleen L. Gallant has over 15 years of experience as a volunteer advocate for people challenged with psoriatic disease. Ms. Gallant developed and drove the IFPA campaign to have WHO recognize psoriasis as a severe, inflammatory noncommunicable disease, which ultimately led to the adoption of the Psoriasis Resolution at the 67th World Health Assembly in 2014 and the 2016 WHO Global Psoriasis Report.



Participates in the following:
Thursday 1/7 16:00-17:00 - Support group sessions and functioning – an interactive workshop with advocates


Julia Gao


Participates in the following:
Thursday 1/7 11:50-12:00 - Psoriasis and Psoriatic Arthritis in Transgender Patients on Hormone Therapy: A Retrospective Comparative Cohort Study


Professor Paolo Gisondi

Paolo Gisondi is associate professor of Dermatology and Director of the school of Specialization in Dermatology and Venereology at the University Hospital of Verona, Italy. He received his degree in Medicine from the Catholic University of Rome in 1997 and then specialized in Dermatology and Venereology at the University of Parma in 2002. Before moving to Verona in 2006, he worked for two years at the Istituto Dermopatico dell'Immacolata of Rome. He is a member of the Italian Society of Dermatology (SIDEMAST), European Academy of Dermatology and Venereology (EADV), Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and the European Dermato-Epidemiology Network (EDEN). He is associate editor of the British Journal of Dermatology (epidemiology Section) and Clinical Dermatology. He has been investigator in several clinical phase III randomized trials investigating the effects of biological therapies in psoriasis. His main scientific interests include the epidemiological, clinical (i.e. comorbidities) and therapeutic aspects of psoriasis and psoriatic arthritis. Apart from clinical research, more than half of his working hours are dedicated to the outpatient clinic and dermatological surgery.



Participates in the following:
Saturday 3/7 15:00-15:30 - SARS-CoV-2 vaccination management in psoriasis and PsA


Professor Dafna Gladman

Dafna D. Gladman, MD, FRCPC is Professor of Medicine, University of Toronto. Dr. Gladman is a Senior Staff Physician at the Toronto Western Hospital, Deputy Director of the Centre for Prognosis Studies in the Rheumatic Diseases, Director of the Psoriatic Arthritis Program, and Co-Director of the University of Toronto Lupus Clinic. She is a Senior Scientist at the Krembil Research Institute and the Schroeder Arthritis Institute.



Participates in the following:
Thursday 1/7 15:00-15:45 - Axial PsA – the AXIS project
Friday 2/7 12:10-13:00 - Potential for prevention of comorbidity


Professor Robert Gniadecki

Dr. Robert Gniadecki received his MD degree from Warsaw Medical School (Poland) in 1991 and three years later he obtained his PhD from the Copenhagen University (Denmark) and became a specialist in dermatology in 2001. In 2010 he was appointed as a full clinical professor at the University of Copenhagen and in 2015 at the University of Alberta, Canada. Dr Gniadecki has served as a president of the Danish Dermatological Society, treasurer of the Canadian Dermatology Foundation. He published >250 peer-reviewed papers and pioneered research in the real-world efficacy of biologics in psoriasis.



Participates in the following:
Saturday 3/7 11:35-12:00 - Con


Dr. Christian Greis

Dr. Christian Greis is senior dermatologist at the Dermatology Department of University Hospital Zurich, Master of Business Administration in E-Health & Digital Transformation and founder of the teledermatology company derma2go AG.



Participates in the following:
Thursday 1/7 10:00-10:50 - Telemedicine as a tool for communication


Professor Chris Griffiths

Chris Griffiths qualified in Medicine from St Thomas’ Hospital Medical School, London and trained in Dermatology in London and Michigan. He was appointed to the Foundation Chair in Dermatology at the University of Manchester in 1994. He was appointed OBE, for services to dermatology, in the 2018 Queen’s New Year Honours.


Professor Griffiths is a previous President of the ESDR, British Association of Dermatologists (BAD), and the International Psoriasis Council. Chris leads the Global Psoriasis Atlas and BADBIR and is Editor-in-Chief of Rook’s Textbook of Dermatology. Chris has a career-long interest in all aspects of psoriasis and is active in global health initiatives including co-founding the Burma Skincare Initiative charity.



Participates in the following:
Wednesday 30/6 13:00-14:00 - Theme of the day - Focus on the Burden of Psoriasis/Psoriatic Arthritis COVID-19 and Vaccinations
Wednesday 30/6 13:00-14:00 - Introduction and global burden of disease


Professor Johan Gudjonsson

Dr. Gudjonsson, MD, PhD. Is the Arthur C. Curtis Professor of Skin Molecular Immunology at the University of Michigan (UM).  Dr. Gudjonsson's research focus is on inflammatory skin diseases.  He has published >180 papers and has received several awards, including from Doris Duke Foundation, and the SID Rising Star Lecture.  He is a member of the American Society for Clinical Investigation (ASCI). He is NIH R01 funded and is the director of an NIH P30 Research Core Center at UM.  He is currently a standing member of the NIH ACTS Study Section and the Board of Scientific Counselors to NIAMS.  



Participates in the following:
Wednesday 30/6 10:30-11:10 - Pathogenesis of psoriasis


Professor Wayne Gulliver


A Dermatologist experienced as a clinician, educator, administrator, clinical and basic science researcher. Has supervised over 250 clinical trials covering many aspects of dermatology with the focus in genetics, psoriasis, wound care, virology and hidradenitis suppurativa. He has more than 100 published papers authored or co-authored, as well as over 200 abstracts authored or co-authored. Professor and Chair of the Discipline of Medicine, Memorial University of Newfoundland (2009-2011), Head of Dermatology, Faculty of Medicine, Memorial University of Newfoundland (1989-2021).



Participates in the following:
Friday 2/7 11:10-11:50 - Can we prevent disease progression in psoriasis?


Briana Halle


Participates in the following:
Friday 2/7 11:50-12:00 - Immune checkpoint inhibitors in patients with preexisting psoriasis associated with manageable disease exacerbations and excellent tumor outcomes


Professor Philip Helliwell

Philip Helliwell is Professor of Clinical Rheumatology at the University of Leeds, UK, and Honorary Consultant Rheumatologist for the Leeds Teaching Hospitals and Bradford Teaching Hospitals NHS Trust.


Dr Helliwell has published over 400 peer reviewed papers. Current and past research in psoriatic arthritis includes treatment paradigms, clinical features and classification of psoriatic arthritis and community-based studies of psoriasis and psoriatic arthritis. He has also published on biomechanics of joints, gait assessment and foot disorders in inflammatory and non-inflammatory arthritis, and epidemiology of rheumatic diseases.



Participates in the following:
Thursday 1/7 14:00-14:45 - Rheumatological manifestations and clinical features


Professor Lars Iversen


Participates in the following:
Saturday 3/7 12:10-13:00 - Is there still a place for topical treatment?


Professor Kenji Kabashima

Dr. Kabashima graduated from Kyoto University in 1996. He started research on bioactive lipid mediators at Kyoto University, which led to a PhD. Currently, he is a chair/professor at the Department of Dermatology, Kyoto University Graduate School of Medicine, Japan, a principal investigator at the SRIS/SIgN, Singapore, and visiting consultant at the National Skin Centre, Singapore. His main interests include the mechanism of inflammatory skin diseases and 3D-visualization of the skin using two-photon microscopy. His hobbies are running and travelling.



Participates in the following:
Wednesday 30/6 14:00-14:45 - New pathways/drivers of immunity


Professor Arthur Kavanaugh

Arthur Kavanaugh is Professor of Medicine at the University of California, San Diego School of Medicine.
Prof. Kavanaugh’s main research interest has been on rheumatoid arthritis (RA) and psoriatic arthritis (PsA). He has been involved in helping to create guidelines for the treatment of patients with rheumatic diseases, including RA and PsA. . Prof. Kavanaugh has authored more than 550 peer reviewed scientific publications as well as being on the editorial board of several journals



Participates in the following:
Wednesday 30/6 11:10-11:50 - Treatment guidelines/best practice PsA


Professor Jo Lambert

Jo Lambert is a senior full professor in dermatology, and academic chair of the Department of Dermatology at Ghent University, Ghent, Belgium. She is past president of the Royal Belgian Society of Dermatology and Venereology, member of the Royal Academy of Medicine of Belgium, board member of the Fondation René Touraine Scientific Committee, past president of the Skin Inflammation and Psoriasis International Network of the FRT, IPC Councilor and chair of the EADV Task Force Psoriasis. Her research interests lie in the improvement of care in immune-mediated inflammatory skin disorders through an evidence-based integrated approach.



Participates in the following:
Saturday 3/7 15:00-15:30 - Are early registry data helpful for risk assessments?
Saturday 3/7 13:00-14:00 - Psoriasis and diet


Professor Mark Lebwohl

Dr. Mark Lebwohl is Dean for Clinical Therapeutics and Chairman Emeritus of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai. He is a past President of the American Academy of Dermatology and Chairman emeritus of the Medical Board of the National Psoriasis Foundation. He has published over 500 peer-reviewed articles and is editor of Treatment of Skin Disease which is now in its 5th edition and is published in English, Chinese, Polish, Portuguese, and Spanish.



Participates in the following:
Saturday 3/7 12:10-13:00 - New topical developments


Mark Lebwohl


Participates in the following:
Wednesday 30/6 12:50-13:00 - Effisayil 1: A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of spesolimab in patients with a generalized pustular psorias
Thursday 1/7 11:50-12:00 - Changes in Patient Perceptions of Psoriatic Arthritis From 2012 to 2020: Results From the UPLIFT Survey


Professor Mats Lekander

Dr. Lekander is a professor of Psychoneuroimmunology at Stockholm University and of Health Psychology at Karolinska Institutet, Sweden. Dr Lekander studies the relation between inflammation, brain and behaviour. Neuroimaging methods are used to study the consequences of peripheral inflammation on the brain. Experimental inflammation is used in humans to understand mechanisms and consequences of immune-to-brain communication, complementing investigations of chronic peripheral inflammatory conditions and co-morbid problems with depression, anxiety and pain.



Participates in the following:
Friday 2/7 15:00-15:45 - Pathogenesis of depression in inflammation (chronic and acute)


Professor Katy Leung


Participates in the following:
Thursday 1/7 10:00-10:50 - The importance of communication in treating persons with chronic, inflammatory disease


MD, PhD Josefin Lysell

Dr Lysell is a senior consultant in the Dermatology department at Karolinska University Hospital (KUS). 


2015 she completed her PhD at the Karolinska Institutet focusing on psoriasis in childhood and adolescence.


Present work involves a half-time clinical post-doctoral position funded by Stockholm Regional Council in combination with clinical work at KUS. Present projects involve translational studies in psoriasis, focusing on guttate psoriasis, and studies exploring the skin "citrullinome" in healthy and inflamed skin. Follow up studies of the pediatric psoriasis cohort is also in pipeline.



Participates in the following:
Friday 2/7 10:00-11:00 - Comorbidity in children and young adults


Dr Satveer Mahil

Dr Satveer Mahil is a Consultant Dermatologist at St John's Institute of Dermatology, Guy’s and St Thomas’ NHS Foundation Trust, London, UK. She graduated from the University of Cambridge and completed integrated academic training in dermatology at St John's Institute of Dermatology. She holds a MRC Clinical Academic Research Partnership Award and her research seeks to optimise outcomes for individuals with inflammatory skin diseases including psoriasis. She is co-director of the PsoProtect and PsoProtectMe registries and director of St John's DermAcademy (dermatology education academy).



Participates in the following:
Wednesday 30/6 16:00-17:00 - Psoriasis and COVID-19 – Findings from PsoProtectMe


Elisa Martini


Participates in the following:
Friday 2/7 13:00-14:00 - The Psoriatic Disease Response Index: Measuring health systems’ responses to psoriatic disease - Global Psoriasis Coalition


Professor Philip Mease

Dr. Mease directs rheumatology research, Swedish Medical Center/Providence St. Joseph Health. Clinical Prof of Med at Univ. of WA. Major research interests: psoriatic arthritis (PsA) and spondyloarthritis (SpA). Research on disease state, outcome measures, determining efficacy & safety of emerging therapies. Over 530 journal articles, numerous abstracts, book chapters. Member of GRAPPA and ASAS and SPARTAN. Active in OMERACT. Scientific director of PsA and SpA arm of Corrona registry. Co-chair of PsA task force, National Psoriasis Foundation; 2019 lifetime achievement award



Participates in the following:
Wednesday 30/6 12:10-12:50 - New treatments/pipeline PsA
Thursday 1/7 15:00-15:45 - Educational projects


Professor Nehal Mehta

Nehal Mehta, MD, MSCE received his BA Summa Cum Lauded in Neuropsychobiology in an Accelerated BA/MD Program from the George Washington University in 1997. In 1997, he studied Biochemistry at Oxford University as a Pembroke Scholar. Dr. Mehta received his degree in Medicine from George Washington University Medical School in 2001 with Distinction. Dr. Mehta completed his internship, residency and Chief Residency in Internal Medicine at the University of Pennsylvania (2001-2005) followed by a fellowship in Cardiovascular Disease at the University of Pennsylvania focusing on nuclear cardiology, lipidology and atherosclerosis risk factors (2005-2009). Dr. Mehta completed a Research Fellowship in Genetic Epidemiology at Penn, and then joined the faculty at Penn for two years. In 2012, he was named the Inaugural Lasker Clinical Research Scholar at the National Institutes of Health’s National Heart, Lung, and Blood Institute.


 


Dr. Mehta has advanced studies of atherosclerosis progression in the context of inflammation. At the NIH, Dr. Mehta directs a prospective cohort study of psoriasis patients in which he is performing vascular imaging in several vascular territories with multiple modalities (PET CT, PET MRI, Coronary CT angiography) before and after treatment of skin disease. Furthermore, his lab studies novel markers in the blood which may characterize immune cells potentially linking psoriasis and atherosclerosis. Dr. Mehta’s combination of in vivo imaging and immune phenotyping demonstrated that treatment of skin disease reduces coronary plaque burden, non-calcified plaque, peri-coronary inflammation and coronary lipid rich necrotic core. Dr. Mehta is a member of the American Society of Clinical Investigation in and has received the NHLBI Director’s Award (2016), and also received the NIH Director’s Award that year in 2018. In 2020, Dr. Mehta became the first Lasker Senior Investigator at the NIH.


 


To date, Dr. Mehta has published over ~200 peer-reviewed manuscripts and editorials. He has lectured at multiple national meetings and has been a keynote and plenary speaker several meetings this past year. He has a performed five visiting professorships at worldwide centers of excellence including Karolinska, Oxford, Glasgow, Madrid and Denmark. His program has CTA sites in Australia, Spain and at various centers around the US. He has two fellowship training grants from the AHA and NPF to train junior faculty, and has four active CRADAs (contracts with industry). Dr. Mehta is a Fellow of the American Heart Association and American College of Cardiology. Dr. Mehta holds membership in the American Medical Association, American Society of Echocardiography, the American Society of Nuclear Cardiology, American Heart Association Council on Prevention/Epidemiology. He has served as Chair at the NIH at two major meetings over the past four years, one on vascular inflammation and the other on coronary CT angiography: (https://videocast.nih.gov/summary.asp?Live=35292).



Participates in the following:
Friday 2/7 14:00-14:45 - Vascular inflammation in chronic inflammatory disease


Paul Mendoza

Paul Mendoza is the Vice President of Psoriasis Philippines and the President of Psoriasis Asia-Pacific. He is the Chairperson of PsorCoach University where he empowers patients to lead other patients. He is part of the Technical Working Group in drafting the National Psoriasis Policy under the Department of Health. He is also part of the Philippine Alliance for Patients with Chronic Illness, Healthy Philippines Alliance, and Alternative Budget Initiative for Health where he engages the Philippine government for patients' rights, access to medicine, social protection, and universal health agendas.



Participates in the following:
Saturday 3/7 10:00-11:00 - The WHO Global report on psoriasis – suggested actions to improve treatment and care for people with psoriasis
Thursday 1/7 16:00-17:00 - Support group sessions and functioning – an interactive workshop with advocates


Dr. Alan Menter

Dr. Alan Menter was born in England; he is a graduate of the Medical School of the University of Witwatersrand, South Africa. In 2010, he created the Dermatology Residency Program at Baylor University Medical Center. Dr. Menter has a long-held interest in psoriasis and psoriatic disease research. In 1994, he co-authored the first gene discovery for psoriasis, published in Science. In August 2004, Dr. Menter co-founded the International Psoriasis Council. His resume lists some 420+ articles, 6 books. In 2020, he was one of 6 USA Dermatologists who received the “Giants of Dermatology” award.



Participates in the following:
Thursday 1/7 13:00-14:00 - Theme of the day: Lifestyle, dealing with daily life problems, latest research and mental health
Thursday 1/7 13:00-14:00 - Psoriatic arthritis for the dermatologist


Joseph F. Merola


Participates in the following:
Thursday 1/7 11:50-12:00 - Changes in Patient Perceptions of Psoriatic Arthritis From 2012 to 2020: Results From the UPLIFT Survey


Professor Ulrich Mrowietz

Ulrich Mrowietz is professor of dermatology at the University Medical Center Schleswig-Holstein, Campus Kiel, Germany. 


Professor Mrowietz is author of more than 356 peer-reviewed publications listed in the Medline database. His h-Index is 61.


Professor Mrowietz is councillor of the IPC, member of the scientific advisory board of the German Psoriasis Association, the Clusters of Excellence “Inflammation at Interfaces” and “Precision Medicine in Chronic Inflammation”.


Professor Mrowietz is the president of the 6th World Psoriasis and Psoriatic Arthritis Conference in July 2021.



Participates in the following:
Wednesday 30/6 10:30-11:10 - Plenary/symposium session – Pathogenesis
Wednesday 30/6 11:10-11:50 - Plenary symposium session – Treatment guidelines
Wednesday 30/6 12:10-12:50 - Plenary/symposium session – New treatments
Wednesday 30/6 14:00-14:45 - Keynote lecture
Wednesday 30/6 15:00-15:45 - Keynote lecture
Thursday 1/7 12:00-12:45 - Keynote lecture
Thursday 1/7 14:00-14:45 - Joint IFPA/ GRAPPA session; Palmoplantar pustulosis
Friday 2/7 12:10-13:00 - Plenary/symposium session - 20 years of biologics
Friday 2/7 14:00-14:45 - Keynote lecture
Friday 2/7 15:00-15:45 - Keynote lecture
Saturday 3/7 10:00-11:00 - Interactive discussion session
Saturday 3/7 11:10-11:35 - Unmet needs session continued
Saturday 3/7 12:10-13:00 - Plenary/symposium session - Topical therapy
Saturday 3/7 15:30-16:15 - Awards session – Poster presentations
Wednesday 30/6 16:00-17:00 - COVID-19 : Vaccination against SARS-CoV-2 in people with psoriatic disease


Professor Luigi Naldi

Dr. Naldi is a qualified Full Professor of Dermatology and the Director of the Department of Dermatology of Ospedale San Bortolo in Vicenza (Italy). He is the founder and president of “Centro Studi GISED,” an academic entity, dedicated to clinical research in Dermatology. He has been a visiting Professor at the Department of Dermatology of the University of Genève, and the Head of the Unit of Clinical Pharmacology and Epidemiology at Ospedali Riuniti di Bergamo (Italy). Dr. Naldi has authored a total of 407 papers with h-index =85 ( June 24, 2021).



Participates in the following:
Thursday 1/7 13:00-14:00 - Lifestyle intervention programs


Professor Alexander Nast

Prof. Dr. Alexander Nast is a consultant dermatologist at Charité – Universitätsmedizin Berlin, Germany. At the Charité hospital he heads the division of evidence based medicine (dEBM). He is the chairman of the German (DDG) and European (EDF) / EuroGuiDerm Guidelines Committee for dermatology. He obtained his medical degree in 2005 at Charité – Universitätsmedizin Berlin, including training at Université René Descartes Paris V (Necker), Paris, France and St. John’s Institute of Dermatology, London, UK. He is an expert in evidence based medicine and the development of guidelines.



Participates in the following:
Wednesday 30/6 11:10-11:50 - Treatment guidelines/best practice psoriasis


Professor Alexander Navarini

Born in Basel, raised in Kantons GR and AG, medical studies in Basel and Paris. Training as MD PhD experimental immunologist in Zurich. Residency in internal medicine at Bruderholzspital, tropical medicine at Swiss Tropical Institute, and dermatology at University Hospital Zurich. Senior resident research fellowship in modern genomics at King’s College London. Was attending physician and deputy head of outpatient clinic at Department of Dermatology, University Hospital Zurich. Since November 2018 Chair of Dermatology at the University Hospital of Basel.



Participates in the following:
Thursday 1/7 14:00-14:45 - Skin manifestations and clinical features
Saturday 3/7 13:00-14:00 - The future of teledermatology


Ellen Nordgren


Participates in the following:
Thursday 1/7 14:00-14:45 - The challenge of living with PPP- Filmed testimonials from people living with PPP


Alexis Ogdie


Participates in the following:
Thursday 1/7 11:50-12:00 - Changes in Patient Perceptions of Psoriatic Arthritis From 2012 to 2020: Results From the UPLIFT Survey


Alexis Ogdie-Beatty

Dr. Alexis Ogdie is Associate Professor of Medicine and Epidemiology, Deputy Director of the Penn Center for Clinical Epidemiology, and Director of the Penn Psoriatic Arthritis and Spondyloarthritis Program at the Perelman School of Medicine, University of Pennsylvania. The mission of her research program is to improve outcomes in PsA by accelerating diagnosis, increasing the focus on meaningful, patient-centered outcomes, and developing and advancing methods for precision medicine.



Participates in the following:
Friday 2/7 10:00-11:00 - Matching comorbidity in psoriasis and PsA


Professor Melissa Oliver

Dr. Oliver completed her training in Pediatrics at Rutgers New Jersey Medical School and Pediatric Rheumatology at Stanford University. She is currently an Assistant Professor in the Division of Pediatric Rheumatology at Indiana University School of Medicine, IN, USA. Her research interests include patient outcomes in juvenile spondyloarthropathy and chronic nonbacterial osteomyelitis populations. She is an active member of the Childhood Arthritis & Rheumatology Research Alliance and leads the OMERACT CNO/SAPHO working group for the development of a core domain and measurement set.



Participates in the following:
Thursday 1/7 14:00-14:45 - Outcomes measures


Professor Jörg Prinz

Jörg C. Prinz is Full Professor of Dermatology and Venereology and deputy chair at the Clinic for Dermatology and Allergology of the Ludwig-Maximilian University (LMU) in Munich, Germany. After one year training in internal medicine at the University clinics of Freiburg and five years of basic immunology research as postdoctoral fellow at the Institute for Immunology of the LMU in Munich, he joined the Clinic for Dermatology and Allergology in 1990, where he founded the Research Group for Immunopathology, focusing on the pathogenesis and management of psoriasis.



Participates in the following:
Friday 2/7 13:00-14:00 - Theme of the day: Access to care and management. Focus on unmet needs
Friday 2/7 13:00-14:00 - Inflammatory disease – a new way of thinking


Professor Lluis Puig

Luis Puig is Director of the Dept. of Dermatology, Hospital de la Santa Creu i Sant Pau (HSCSP) and Professor of Dermatology at the Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. He is or has been Board Member of the EADV (2013-2019), Co-chair of the Psoriasis Task Force of the EADV (2018-), President of the Psoriasis International Network (2016-2020), Councilor (2012-) and Board Member (2018-) of the International Psoriasis Council (2012-), and Member of the GRAPPA Education and Steering Committees (2020-2023).



Participates in the following:
Saturday 3/7 11:35-12:00 - Pro


Professor Kristian Reich

Prof. Dr. med. Kristian Reich is Professor for Translational Research in
Inflammatory Skin Diseases at the Institute for Health Services Research in
Dermatology and Nursing, University Clinic Hamburg-Eppendorf and
partner at the Dermatologikum Berlin. In May 2021, he co-founded
MoonLake Immunotherapeutics.
Reich finished his doctoral thesis in mucosal immunology with summa cum
laude 1995 in Munich and his Habilitation (PhD equivalent) in skin
immunology following his final exam as consultant dermatologist in
Göttingen. In 2003 he was appointed University Professor and Vice
Director of the Dermatology Department at the Georg-August-Universität
Göttingen.
His main research interests include genetic and immunologic mechanisms
of cutaneous inflammatory disorders and cancer and the development of
new therapies for skin diseases such as psoriasis and atopic dermatitis. He
published more than 300 articles in international peer-reviewed journals,
including The Lancet, the New England Journal of Medicine, the Journal of
Immunology and the Journal of Allergy and Clinical Immunology. Prof.
Reich chairs the scientific committee of the German Psoriasis Registry
PsoBest, is member of the board of the ProDerma and the AlfredMarchionini foundation. He is counselor of the International Psoriasis
Council and the International Eczema Council.
Prof. Reich received numerous prices and rewards including the HerbertHerxheimer Research Price of the German Society for Immunology and
Allergology (2003), the R.K. Schachter Lectureship (2012), and the Stars of
the Academy Award of the American Academy of Dermatology (2016)



Participates in the following:
Wednesday 30/6 12:10-12:50 - New treatments/pipeline psoriasis


Professor Christopher Ritchlin

Christopher Ritchlin, MD, MPH is Professor and Chief of the Allergy, Immunology and Rheumatology Division of the University of Rochester Medical Center. His primary research interests are centered on the study of osteoimmunologic mechanisms that underlie pathologic bone alterations in psoriatic arthritis. His research team also examines cellular, serum and imaging biomarkers of arthritis in psoriasis patients. He is the co-founder of the IPART Registry and GRAPPA. He is also involved in the development of new therapies for psoriatic arthritis and pursuing investigations into the potential role of the lymphatic system in joint flare.



Participates in the following:
Saturday 3/7 10:00-11:00 - Unmet needs in psoriatic arthritis


Prof. Dr. Ricardo Romiti

Ricardo Romiti, MD, PhD, is responsible for the Psoriasis Unit at the Department of Dermatology of the University of São Paulo, Brazil, and works as director and clinical Professor of Dermatology also at the University of São Paulo.
Professor Romiti is the editor of the Brazilian Consensus of Psoriasis 2020 of the Brazilian Society of Dermatology (SBD), has authored or co-authored numerous papers published in national and international dermatology journals and is the editor of five books with a focus on psoriasis. In addition, Professor Romiti is currently Board Director of the International Psoriasis Council (IPC).



Participates in the following:
Saturday 3/7 10:00-11:00 - Health economics and access to treatment


Dr Roop Saini

Dr. Roop Saini, a young and dynamic Consultant Dermatologist from Nairobi, Kenya. I'm currently working at the Kenyatta National Hospital which is the biggest Teaching and Referral Hospital in East and Central Africa. I attained my undergraduate medical training from the University of Nairobi and my postgraduate training in Dermatology from Cardiff University in the United Kingdom. I am currently an Honorary Lecturer at the University of Nairobi, an Executive member of the Kenya Association of Dermatologists and the Scientific Chair for the upcoming African Society of Dermatology and Venereology (ASDV) Conference.



Participates in the following:
Friday 2/7 16:00-17:00 - Putting psoriasis into focus at a national level – unmet needs in Africa – Learnings from Kenya


Professor Lone Skov

Lone Skov is a professor and senior physician in the Department of Dermatology and Allergy at the University of Copenhagen, Herlev and Gentofte Hospital.
She has long-standing research interests in chronic, inflammatory skin diseases where the immune system plays a key role, with special interest in psoriasis. She has experience conducting clinical studies, clinical trials, and basic science research.
Lone has published more than 250 PubMed-cited articles and is Section Editor for Acta Derm Venereol on psoriasis.



Participates in the following:
Saturday 3/7 13:00-14:00 - Session 7: International Psoriasis Council – On latest research and updates
Saturday 3/7 13:00-14:00 - Welcome and introduction
Saturday 3/7 13:00-14:00 - IPC’s disease severity classification: What it means in the clinic
Friday 2/7 10:00-11:00 - Comorbidity in adult psoriasis


Dr Rachel Sommer

Dr. Sommer investigates the experienced health of people with skin diseases, taking into account physical, psychological and social aspects. The research focuses on people-centered health care, as claimed for by the WHO. Dr. Sommer is working as a researcher at the Institute for Health Services Research in Dermatology and the Nursing Professions (IVDP) at the University Medical Center Hamburg-Eppendorf (UKE) since September 2016. She studied public health and epidemiology at the Hogeschool Zuyd (NL) and the Charité Berlin. At the IVDP, she leads the research area People-Centered Health Care.



Participates in the following:
Wednesday 30/6 15:00-15:45 - Patient reported outcomes measures – measuring wellbeing not only burden of disease


Professor Mona Ståhle


Participates in the following:
Wednesday 30/6 14:00-14:45 - Keynote lecture
Wednesday 30/6 15:00-15:45 - Keynote lecture
Thursday 1/7 11:00-11:45 - Keynote lecture
Friday 2/7 10:00-11:00 - Plenary/symposium session - Comorbidity update
Friday 2/7 11:10-11:50 - Session continues - Prevention series
Friday 2/7 14:00-14:45 - Keynote lecture
Friday 2/7 15:00-15:45 - Keynote lecture
Saturday 3/7 11:35-12:00 - “Hot topic session” – hit early, hit hard
Saturday 3/7 14:00-14:45 - Keynote lecture
Saturday 3/7 15:30-16:15 - Awards session – Poster presentations


Diamant Thaçi


Participates in the following:
Friday 2/7 12:10-13:00 - Looking back and looking ahead – long-term safety, risk management and future potential
Wednesday 30/6 12:50-13:00 - Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Compared With Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Efficacy and Safety Results From the Phase


Dr Colin Theng


Participates in the following:
Wednesday 30/6 13:00-14:00 - Theme of the day - Focus on the Burden of Psoriasis/Psoriatic Arthritis COVID-19 and Vaccinations
Wednesday 30/6 16:00-17:00 - Session 2: Psoriatic disease and COVID-19
Thursday 1/7 13:00-14:00 - Theme of the day: Lifestyle, dealing with daily life problems, latest research and mental health
Thursday 1/7 16:00-17:00 - Session 4: Psoriatic disease and its impact on mental health
Friday 2/7 13:00-14:00 - Theme of the day: Access to care and management. Focus on unmet needs
Friday 2/7 16:00-17:00 - Session 6: Focus on unmet needs: Taking global knowledge and implementation at national level


Professor William Tillet

Dr William Tillett is a consultant rheumatologist at the Royal National Hospital for Rheumatic Diseases and senior lecturer in the department of pharmacy and pharmacology at the University of Bath, UK. He undertook his doctoral fellowship in patient centered outcome in psoriatic arthritis and had published more than 170 original articles, conference proceedings or book chapters on the assessment and treatment of Psoriatic Arthritis (PsA). Dr Tillett currently co-chairs a number of PsA research working groups including the GRAPPA-OMERACT group.



Participates in the following:
Thursday 1/7 15:00-15:45 - Composite measures


Professor Peter van de Kerkhof

Profile of Peter CM van de Kerkhof Prof dr Peter CM van de Kerkhof started his training in Dermatology and his research on psoriasis in 1979 at the department of dermatology of the Radboud University Medical Centre in Nijmegen the Netherlands. From 1991 until 2018 he was the chairman of that department .Under his guidance there was an active program on psoriasis and non-melanoma skin cancer . His research contributions were focused on the pathogenesis and treatment of psoriasis. The transition from the symptomless skin to the psoriatic lesion were studied over the years, concluding that various aspects of innate immunity are fundamental to the disease. He has been a principal investigator in many clinical trials. Furthermore, he has worked in international consortia on the positioning of innovative treatments in psoriasis. His contributions to International Dermatology : 1994 - 1998 Secretary Treasurer European Society for Dermatological Research 1997 - Founding member European Dermatology Forum 1998 - 1999 President European Society for Dermatological Research 2001 - 2002 Secretary General European Dermatology Forum 2002 - 2003 President European Dermatology Forum 2003 - 2009 Member of the Scientific Committee of the Foundation René Tourraine 2011 – 2013 President International Psoriasis Council 2009 - 2013 Board member European Academy for Dermatology and Venereology 2006 – 2018 Board of Directors International Psoriasis Council, Past President 2014 - 2018 Board member UEMS section Dermatology 2010- Advisory board international federation of psoriasis associations 2014- Chair of the scientific board of Dutch burn wound foundation He has published over 800 papers in peer reviewed journals . Currently he is a senior Professor of the Radboud University and Chief Medical Officer of the International Psoriasis Council.



Participates in the following:
Wednesday 30/6 16:00-17:00 - Session 2: Psoriatic disease and COVID-19
Wednesday 30/6 16:00-17:00 - Insights on how COVID-19 affects the care of patient: Innovations in the research landscape in the past year


Dr. Hoseah Waweru


Participates in the following:
Wednesday 30/6 13:00-14:00 - Theme of the day - Focus on the Burden of Psoriasis/Psoriatic Arthritis COVID-19 and Vaccinations
Wednesday 30/6 16:00-17:00 - Session 2: Psoriatic disease and COVID-19
Thursday 1/7 13:00-14:00 - Theme of the day: Lifestyle, dealing with daily life problems, latest research and mental health
Thursday 1/7 16:00-17:00 - Session 4: Psoriatic disease and its impact on mental health
Friday 2/7 13:00-14:00 - Theme of the day: Access to care and management. Focus on unmet needs
Friday 2/7 16:00-17:00 - Session 6: Focus on unmet needs: Taking global knowledge and implementation at national level
Saturday 3/7 16:45-17:15 - Complementary Program – IFPA 50th Anniversary and Awards


Professor Wolfgang Weger


Participates in the following:
Saturday 3/7 12:10-13:00 - Measures to improve adherence to topical treatment


Lars Werner


Participates in the following:
Friday 2/7 13:00-14:00 - Climate treatment in the Nordic region - Presentation white paper


Lucy Westerman

Lucy is passionate about improving health for all through health promotion and disease prevention policy, and leads the NCD Alliance’s noncommunicable disease prevention work through policy and advocacy. Her focus is on nutrition and healthy diets, physical activity, alcohol, and scrutinising cross cutting issues such as social, commercial and environmental influences on health. Lucy also co-ordinates NCD Alliance's #ActOnNCDs and Global Week for Action on NCDs campaign each September. Lucy holds a Master of Public Health and undergraduate degrees in Health (Health Promotion), Arts (Sociology), Science (Nutrition).



Participates in the following:
Thursday 1/7 13:00-14:00 - A focus on alcohol and food systems; the latest in the prevention policy landscape for the psoriasis community

IFPA Secretariat
Gustavslundsvägen 143
167 51 Bromma, SWEDEN
ifpa-pso.com

The International Federation of Psoriasis Associations is a non-profit organization representing millions of people living with psoriasis or psoriatic arthritis worldwide.

Conference Bureau:
Meetagain Konferens AB
Email: ifpaworldconference@meetagain.se